Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

About this update from Protagonist Therapeutics, Inc.

NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in March 2026. TD Cowen 46th Annual Health Care Conference; Boston, MA - March 2-4, 2026Format: Fireside ChatDay/Time: Tuesday, March 3 at 11:50 A.M. ETWebcast: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/6QuKhqDYvNSrPH8co9v5gd Leerink Global Healthcare Conference; Miami, FL - March 8-11, 2026Format: Fireside ChatDay/Time: Monday, March 9 at 4:20 P.M. ETWebcast: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/K8FdPptAY5cyfndeY9RPP9 Jefferies Biotech on the Beach Summit; Miami, FL - March 10-11, 2026Format: One-on-one MeetingsDay/Time: Tuesday, March 10 Citizens Life Sciences Conference; Miami, FL - March 10-11, 2026Format: Fireside ChatDay/Time: Wednesday, March 11 at 1:05 P.M. ETWebcast: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/UWj58vHDxUk6PseGJr4ebs Barclays 28th Annual Global Healthcare Conference; Miami, FL - March 10-12, 2026Format: Fireside ChatDay/Time: Thursday, March 12 at 11:30 A.M. ETWebcast: https://cc.webcasts.com/barc002/031026a_js/?entity=30_ESKWJT8 If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative. A replay of the presentations will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event. About ProtagonistProtagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist ...

View stock analysis, news, and events for Protagonist Therapeutics, Inc.